Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ESSA Pharma ( (EPIX) ) has shared an announcement.
On August 14, 2025, ESSA Pharma Inc. announced a return of capital distribution totaling US$80,000,000 to its shareholders as part of the winding-up of its business following a transaction with XenoTherapeutics, Inc. The distribution, scheduled for August 22, 2025, will result in shareholders receiving approximately $1.69 per common share. Due to the distribution exceeding 25% of the share price, Nasdaq has implemented ‘due bill’ trading from August 19 to August 25, 2025, affecting the entitlement to the distribution for buyers and sellers during this period.
The most recent analyst rating on (EPIX) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Average Trading Volume: 248,217
Technical Sentiment Signal: Sell
Current Market Cap: $84.69M
Learn more about EPIX stock on TipRanks’ Stock Analysis page.